english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Covid-19 and hydroxychloroquine: caution

 NEWS UPDATE  Hydroxychloroquine was not shown to be effective in a randomised trial in 30 patients with covid-19, the results of which were published in China in early March 2020. The hypothesis that this drug sometimes worsens covid-19 has not been ruled out. Short-course treatment with hydroxychloroquine carries a risk of various adverse effects, some of which can be fatal, especially in the event of an overdose.
30 March 2020

Pillflix3D°: an Innovative new manufacturing process that could revolutionise the way we solve medicines shortages

1 April 2020

• Watch out for acute shortages... of critical thinking!

Poisson d'avrilTo err is human, but when computers are involved, things can really get out of hand. Our ever-encroaching digital magic too often causes humans to put their critical faculties on hold. In these days of chronic drug shortages, contagious panic and an acute dependence on virtual everything, it's more vital than ever to hang on to one's good old-fashioned thinking cap.
1 April 2020

Lithium during pregnancy: malformations, fetotoxicity and uncertain long-term effects

FEATURED REVIEW Outside the context of pregnancy, lithium is the standard "mood stabiliser" for the treatment of bipolar disorder. What are the main known short-term and long-term consequences of in utero exposure to lithium?
Full review (3 pages) available for download by subscribers.
1 April 2020

In the April issue of Prescrire International: Denosumab (Prolia°) and steroid-induced osteoporosis

FREE DOWNLOAD Denosumab (Prolia°) has an unfavourable harm-benefit balance in the prevention of osteoporotic fractures. It has also been authorised in the prevention of osteoporosis induced by prolonged corticosteroid therapy. How do Prescrire's editors rate denosumab in this situation?
Full text available for free download.
1 April 2020

Drugs in 2019: a brief review

Eleven of the 108 new drugs, combinations, dose strengths, pharmaceutical forms or indications analysed and rated in our French edition in 2019 constituted a notable therapeutic advance, improving patient care in a variety of fields: haemophilia, various cancers, HIV infection, hepatitis C and rare diseases.
1 April 2020

Drugs in 2019: therapeutic advances, compared with the previous 9 years

GRAPHICS From Prescrire's recap "Drugs in 2019: a brief review", graphics comparing the therapeutic advances during 2019 with the advances made in prior years, along with a table summarising Prescrire's ratings of new products and indications over the past 10 years. 
1 April 2020

France's Mediator° disaster: creating awareness around conflicts of interest

1 April 2020

Zolgensma°: the drug of extremes

For some years now, the escalating cost of new drugs has increasingly threatened access to health care. In 2019, Zolgensma° (onasemnogene abeparvovec-xioi) reached the absurd price of about 2 million euros for the single injection that is required to treat each patient.
1 April 2020

Covid-19 and drug trials: what to make of the initial results?

 NEWS UPDATE  As of 23 March 2020, there are no relevant clinical trial results demonstrating the efficacy of hydroxychloroquine, either alone or in combination with azithromycin. And no efficicacy has been proven for the lopinavir + ritonavir combination in severe covid-19, according to the results of a randomised controlled trial. Until more is known, the hypothetical efficacy of the proposed treatment must be weighed against its known or predictable adverse effects, to avoid making things even worse.
23 March 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90